Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


SDS Biotech maintains sales growth at nine months

Japanese agrochemical company SDS Biotech recorded sales of ¥6,932 million ($89 million at the current rate) in the first nine months of 2011, up 2.4% on the same period in 2010. However, operating income was down 56.4% to ¥208 million ($3 million). Fungicide sales rose by 8.7% to ¥2,962 million ($38 million), due to strong sales of daconil-based products in the Philippines. Rice herbicides were up 1.7% to ¥2,338 million ($30 million), led by sales of benzobicyclon technical in South Korea. However, the company notes lower Japanese sales in both sectors. Non-crop pesticides increased by 5.8% to ¥1,144 million ($15 million). Sales declines were seen for insecticides, down 27.8% to ¥345 million ($4 million) and other pesticides, down 23.9% to ¥141 million ($2 million). The company maintains its forecast of full-year sales growth of 2.4%, coupled with a 34.2% drop in operating income ( Agrow No 619, p 8). This was based on a decision to accept lower prices in a bid to secure market share against overseas generic products.



What to read next




Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts